A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Invasion that Showed Favorable Prognosis after Combined External Radiation Therapy and Sorafenib Therapy.
10.17998/jlc.2016.16.2.134
- Author:
Namyoung PAIK
1
;
Dong Hyun SINN
;
Hee Chul PARK
;
Woo Kyung JEONG
;
Min Sun KIM
;
Ji Hye KIM
;
Bumhee YANG
Author Information
1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. dh.sinn@samsung.com
- Publication Type:Case Report
- Keywords:
Hepatocellular carcinoma;
Sorafenib;
Radiation therapy
- MeSH:
Carcinoma, Hepatocellular*;
Hepatitis B, Chronic;
Humans;
Middle Aged;
Portal Vein*;
Prognosis*;
Response Evaluation Criteria in Solid Tumors;
Thrombosis
- From:Journal of Liver Cancer
2016;16(2):134-138
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is dismal that the median survival is 2 to 4 months without treatment. Sorafenib, the standard regimen of advanced HCC, can prolong median survival only 1.5 months. A 50-year-old man with a history of chronic hepatitis B was diagnosed advanced HCC with PVTT. By a multidisciplinary medical team approach, the combination of 3-demensional conformal radiation therapy with sequential sorafenib was challenged. 4 months after initiation of treatment, he achieved partial response as modified response evaluation criteria in solid tumors criteria. Sorafenib was continued so far, and stable disease has been maintained up to now, without significant adverse effect.
